[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pain-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pain-syndrome":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,50,103,126,156,177,206,228,249,277,326,347,374,414,448,468],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100643683","prospective-case-series-evaluating-6-month-and-12-month-outcomes-after-cryoneurolysis-for-chronic-pain-100643683",false,"NCT07639060","Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain","Inclusion Criteria:\n\n* Diagnosis of chronic pain (generally pain duration of at least 3-6 months) localized to an anatomical region appropriate for cryoneurolysis as determined by the treating physician.\n* Planned cryoneurolysis procedure as part of standard clinical care.\n* Ability to provide written informed consent.\n* Ability and willingness to complete baseline and follow-up questionnaires.\n\nExclusion Criteria:\n\n* Cryoneurolysis performed as part of a separate investigational trial in which data sharing is not permitted.\n* Active infection or other clinical contraindication to the procedure as determined by the treating clinician.\n* Life expectancy of less than 12 months in the judgment of the treating clinician.\n* Any condition that, in the investigator's opinion, would interfere with study participation or completion of follow-up, such as severe psychiatric instability or active substance use that precludes reliable follow-up","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","OBSERVATIONAL","To prospectively describe patient-centered and health utilization outcomes through 12 months after cryoneurolysis performed as routine clinical care for chronic pain at Yale.",[23,24,25,26,27,28,29,30,31,32,33,34,35,36],"Chronic Pain","PERIPHERAL NEUROPATHY","Occipital Neuralgia","Chronic Hip Pain","Hip Osteoarthritis","Knee Osteoarthritis","Spasticity","Chronic Low Back Pain","Lumbar Spondylosis","Cervical Spondylosis","Shoulder Arthritis","Causalgia","Chronic Pain Syndrome","Chronic Neck Pain","RECRUITING","2026-08-19",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":41},"2026-06-20",{"date":45,"type":19},"2028-07",{"name":47,"class":48},"Yale University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":75,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100646071","phase-1-regenerative-medicine-for-joint-hypermobility-and-instability-100646071","NCT07688096","Regenerative Medicine for Joint Hypermobility and Instability","Regenerative Medicine for Joint Hypermobility and Instability: A Prospective, Open-Label, Single-Arm, Step-Care Clinical Study","Inclusion Criteria:\n\n* Adults age 18 years or older, any gender.\n* Symptomatic joint hypermobility or instability attributable to one of the following:\n\n  1. hEDS diagnosed using the 2017 International Classification of the Ehlers-Danlos Syndromes diagnostic criteria;\n  2. HSD classified using the 2017 framework (generalized, peripheral, localized, or historical HSD) with Beighton scoring; or\n  3. post-traumatic joint instability with ligamentous injury documented by examination and\u002For imaging.\n* Objective evidence of instability or clinically relevant hypermobility at one or more target joints, defined as at least one of:\n\n  1. a positive joint-specific instability provocation test on standardized physical examination;\n  2. generalized hypermobility (Beighton score ≥ 5\u002F9 for adults) or documented joint-specific hypermobility at the target joint; or\n  3. imaging evidence of ligamentous laxity or injury at the target joint (dynamic ultrasound, stress radiograph, or MRI).\n* Pain attributable to the target joint for at least 3 months.\n* Baseline pain score of 4 or greater on a 0-10 numeric rating scale.\n* Failure of conservative treatment, including at least 6 weeks of physical therapy directed at the affected joint(s).\n* Not currently using NSAIDs and willing to avoid NSAIDs during the active treatment period, when clinically appropriate.\n* Able to provide informed consent and to comply with study procedures and follow-up.\n\nAdditional eligibility for the Hyaluronic Acid (HA) alternative pathway - a participant may enter the HA pathway if ALL of the following apply, in addition to the inclusion criteria above:\n\n* Has completed at least one regenerative medicine phase (dextrose, PRP, or doxycycline) and either\n\n  1. was classified as an inadequate responder at the phase decision point (GPI \\\u003C 40%) and declined further regenerative rotation,\n  2. completed all available regenerative phases without adequate response, or\n  3. experienced an adverse reaction during a regenerative phase that, in the investigator's judgment, contraindicates further regenerative treatment.\n* A minimum waiting period of 4 weeks has elapsed since the last regenerative medicine treatment attempted, to allow resolution of post-injection effects before HA administration.\n* The target joint(s) have clinical or imaging features amenable to HA viscosupplementation (e.g., articular\u002Fosteoarthritic pain component identifiable on examination or imaging).\n* No contraindication to HA (see Exclusion Criteria).\n\nExclusion Criteria:\n\n* Impaired decision-making capacity that precludes valid informed consent.\n* Active local or systemic infection.\n* Known allergy or contraindication to study injections, local anesthetics, iodinated contrast (if fluoroscopy is planned), or required procedural materials.\n* Known hypersensitivity or intolerance to tetracycline-class antibiotics, including doxycycline (relevant to the doxycycline treatment phase).\n* Mast cell activation syndrome (MCAS) or other mast cell disorder that, in the investigator's judgment, elevates the risk of injection-related hypersensitivity or systemic reactions.\n* Active autoimmune or systemic inflammatory connective-tissue disease that, in the investigator's judgment, may confound the response to regenerative treatment or increase procedural risk.\n* Known hypersensitivity to sodium hyaluronate or to the specific HA product to be used (Visco-3); active skin disease or infection over the planned injection site; venous or lymphatic stasis in the limb of the planned injection.\n* Active malignancy or anticancer treatment within the prior 12 months; a prior malignancy in documented remission may be enrolled at the investigator's discretion with documented rationale.\n* Uncontrolled diabetes mellitus, defined as HbA1c ≥ 8.5% on the most recent value within the prior 3 months; the investigator may also exclude for other objectively documented diabetes-related procedural or healing risk.\n* Prior joint replacement at the target joint.\n* Planned surgery during study participation.\n* Corticosteroid injection to the target joint(s) within the prior 6 weeks.\n* Concurrent enrollment in another interventional study for the same pain condition.\n* Active litigation or disability claim related to the target condition (to limit secondary-gain confounding of self-reported outcomes).\n* Pregnancy, or unwillingness to undergo pregnancy testing when fluoroscopy is planned (persons of childbearing potential).\n* Inability to comply with study procedures or follow-up.",{"count":58,"type":19},100,"INTERVENTIONAL",[61,62],"PHASE1","PHASE2","This clinical trial is designed to evaluate whether a stepwise injection-based treatment approach can reduce pain and improve function in adults with joint hypermobility, connective tissue laxity, and joint instability.\n\nJoint hypermobility occurs when joints move beyond their normal range, often because of looser connective tissue. For some patients, this can contribute to chronic pain, recurrent instability, reduced function, and disability. This study focuses on adults with hypermobile Ehlers-Danlos syndrome (hEDS), hypermobility spectrum disorder (HSD), or joint instability after injury who have already completed physical therapy without adequate relief.\n\nThe main question this study aims to answer is whether the first treatment step, dextrose prolotherapy, can reduce pain by 40% or more two weeks after the second injection.\n\nParticipants will receive treatment in a step-by-step sequence, based on their response:\n\nStep 1: Dextrose prolotherapy A dextrose-based injection used to stimulate a healing response in ligament, tendon, or joint-supporting tissue.\n\nStep 2: Platelet-rich plasma (PRP) An injection prepared from the participant's own blood, designed to support tissue repair and recovery.\n\nStep 3: Doxycycline injections A low-dose injectable treatment used in this study to help protect joint-supporting tissue. It is not being used to treat infection.\n\nAlternative option: Hyaluronic acid injections An injection into the joint that may be offered if the earlier treatment steps do not provide enough improvement.\n\nEach treatment step begins with two injections, given approximately two weeks apart. If a participant improves by 40% or more, they may continue with that treatment pathway. If they do not improve enough, they may be offered the next step in the study.\n\nParticipants will be followed for up to 12 months, with study visits used to monitor pain, function, treatment response, and safety.",[65,66,67,68,69,35,70,71,72,73,74],"Ehlers-Danlos Syndrome Hypermobility Type (hEDS)","Ehlers-Danlos Syndrome (EDS)","Joint Hypermobility","Joint Instability","Hypermobility Spectrum Disorder","Musculoskeletal Pain","Sprain","Subluxation","Dislocation","Craniocervical Disfunction",[76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,72,91,74,92],"prolotherapy","dextrose prolotherapy","platelet-rich plasma","PRP","doxycycline","regenerative medicine","joint hypermobility","hEDS","hypermobile Ehlers-Danlos syndrome","viscosupplementation","hyaluronic acid","step-care","ligament instability","MMP inhibition","dislocation","CCI","Craniocervical instability","NOT_YET_RECRUITING","2026-07-08",{"date":96,"type":41},"2026-07-10",{"date":98,"type":19},"2026-07-15",{"date":100,"type":19},"2028-12-31",{"name":102,"class":48},"Manhattan Pain Medicine, PLLC",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":59,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":49},"100645403","docktales-for-chronic-pain-100645403","NCT07680894","DockTales for Chronic Pain","Evaluating Feasibility and Acceptability of DockTales for Chronic Pain","Inclusion Criteria:\n\n* Age ( 18-88 years old)\n* English speaker (written and spoken)\n* Chronic pain for at least 3 months\n* Smartphone\u002Ftext messaging capability\n\nExclusion Criteria:\n\n* Any personal history of mania, schizophrenia, or other psychoses\n* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.\n* Pregnancy or breast feeding\n* Impaired or uncorrected hearing","88 Years",{"count":112,"type":19},60,[114],"NA","This study will evaluate the feasibility and acceptability of DockTales, a mobile health tool designed for adults with chronic pain. DockTales supports pain and sleep tracking through brief diaries, body-map pain reporting, reflective journaling, visual summaries, and optional AI-supported interaction. The study will be conducted completely remotely. Participants will complete 2 weeks of DockTales use and 2 weeks of REDCap-based daily monitoring, with the order randomized. The main goal is to determine whether DockTales is usable, acceptable, engaging, and practical for adults with chronic pain compared with standard REDCap monitoring.",[23,35],"2026-06-25",{"date":119,"type":41},"2026-07-02",{"date":121,"type":19},"2026-07-17",{"date":123,"type":19},"2027-10-24",{"name":125,"class":48},"University of Maryland, Baltimore",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":134,"minAge":16,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":59,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100625929","intraoperative-bupivacaine-injection-to-reduce-acute-and-chronic-pain-after-tvttvt-o-surgery-randomized-double-blind-trial-100625929","NCT07429019","Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT\u002FTVT-O Surgery. Randomized Double-Blind Trial","Reduction of Post-surgery Pelvic Pain by Bupivacaine Injection During TVT\u002F TVT-O Procedure","PAIN-TVT","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Scheduled to undergo vaginal surgery including TVT or TVT-O procedure for stress urinary incontinence\n* Able and willing to provide written informed consent\n* Willing to complete postoperative follow-up assessments for at least 6 months\n\nExclusion Criteria:\n\n* Planned concomitant abdominal, laparoscopic, or robotic surgery\n* Pre-existing chronic pelvic pain\n* Diagnosis of fibromyalgia\n* Diagnosis of endometriosis\n* Inability to complete follow-up assessments\n* Inability to provide informed consent","FEMALE",{"count":112,"type":19},[114],"This randomized, double-blind controlled trial will evaluate whether intraoperative injection of bupivacaine at the sling insertion site reduces postoperative pelvic and thigh pain in women undergoing TVT or TVT-O surgery for stress urinary incontinence. Women aged 18 years and older scheduled for vaginal surgery including a mid-urethral sling procedure will be randomly assigned to receive either 0.5% bupivacaine or saline injection at the surgical site at the end of the procedure.\n\nPostoperative pain will be assessed using the Numerical Rating Scale (NRS) within 24 hours after surgery, at one month, and at least six months postoperatively. The study will also evaluate opioid consumption and examine the relationship between early postoperative pain and the development of chronic postsurgical pain. The results may help determine whether local anesthetic injection during sling surgery can improve short- and long-term pain outcomes.",[139,140,35,141],"Pain After Surgery","PSP","Local Anesthesia Infiltration",[143,144,145,146,147],"TVT","TVTO","Mid Urethral Sling","pain","chronic pain syndrom",{"date":149,"type":41},"2026-06-23",{"date":151,"type":19},"2026-07-01",{"date":153,"type":19},"2027-10-01",{"name":155,"class":48},"Hadassah Medical Organization",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":59,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100628972","spinal-cord-stimulation-for-refractory-pain-randomized-controlled-trial-the-pacstim-rct-100628972","NCT07468591","Spinal Cord Stimulation for Refractory Pain Randomized Controlled Trial: the PAcStim RCT","Placebo Versus Active Spinal Cord Stimulation for Refractory Pain Randomized Controlled Trial: the PAcStim RCT","PAcStim","Inclusion criteria\n\n* Age 18 years or older\n* Severe NP in the axial locations (neck and back) and\u002F or the limbs\n* Undergoing an SCS implantation with a PF device\n\nExclusion criteria\n\n* Previously implanted with an SCS device\n* Not fluent in English\n* Unable to provide written informed consent",{"count":165,"type":19},90,[114],"Neuropathic pain affects 6-10% of the global population and is poorly managed - current drug treatments succeed in only \\~25% of patients. Spinal cord stimulation (SCS) modulates pain by electrically stimulating spinal dorsal column fibres. The newer paresthesia-free mode (PF-SCS, 500-10,000 Hz) appears more effective and tolerable than traditional paresthesia-based SCS, with superior outcomes shown in the SENZA-RCT. All promising PF-SCS studies have been unblinded, making them susceptible to placebo effects. The one blinded RCT that exists had significant methodological flaws (no washout period, single baseline measurement) that biased results toward the null. A blinded, multi-centre, crossover RCT in 90 patients comparing 6 weeks of active PF-SCS vs. 6 weeks of placebo stimulation, with a 2-week washout in between - designed to correct the flaws of the prior trial and definitively establish whether PF-SCS works beyond placebo.",[35],"2026-06-04",{"date":171,"type":41},"2026-06-08",{"date":151,"type":19},{"date":174,"type":19},"2027-12-01",{"name":176,"class":48},"University Health Network, Toronto",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":15,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":49},"100617937","interoceptive-awareness-and-function-in-adolescents-with-chronic-pain-100617937","NCT07325110","Interoceptive Awareness and Function in Adolescents With Chronic Pain","Study Group:\n\nInclusion Criteria:\n\n1. Adolescents seen as new patients in the pain clinic at Connecticut Children's\n2. Referred to occupational therapy services.\n3. Adolescents diagnosed with a form of chronic pain.\n4. Between the ages of 11 and 21 years at time of enrollment.\n5. If over 18, the ability to understand and willingness to sign the informed consent document or the ability to use the short form process.\n6. If under 18, the parent\u002Flegal guardian, has the ability to understand and willingness to sign the informed consent document or the ability to use the short form process.\n7. Adolescents between the ages of 11 and less than 18 years with the ability to understand and willingness to sign assent.\n8. Adolescents who agree to therapeutic yoga as a planned part of their occupational therapy treatment plan.\n\nExclusion Criteria:\n\n1. Adolescents not receiving yoga as an element of their occupational therapy treatment plan.\n2. Adolescents with a cognitive impairment that would impede their ability to participate.\n3. Adolescents with a neuromuscular diagnosis, such as Cerebral Palsy, Spinal Muscular Atrophy, and Muscular Dystrophies, that are not appropriate for yoga as an element of their treatment plan for this study.\n4. Adolescents unwilling to complete surveys to participate in this research study.\n5. Adolescents who are currently actively practicing yoga\n6. Adolescents who are currently receiving occupational therapy at another location.","11 Years","21 Years",{"count":186,"type":19},49,"The main objectives of this study are to compare the levels of interoceptive awareness and self-reported function pre and post completion of an occupational therapy treatment plan. The target population are adolescents aged 11-21 years that are diagnosed with chronic pain and are seen through the Pain Team at Connecticut Children's. The primary aims are:\n\n* To compare the reported levels of interoceptive awareness in adolescents with chronic pain before and after their occupational therapy treatment plan.\n* To compare the reported levels of function in adolescents with chronic pain before and after their occupational therapy treatment plan.",[23,35,189],"Pain, Chronic",[191,192,193,194,195,196],"chronic pain","adolescents","interoceptive awareness","function","occupational therapy","yoga","2026-04-23",{"date":199,"type":41},"2026-04-27",{"date":201,"type":41},"2026-02-25",{"date":203,"type":19},"2028-12",{"name":205,"class":48},"Connecticut Children's Medical Center",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":59,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":49},"100415439","mind-body-syndrome-therapy-for-chronic-pain-100415439","NCT04689646","Mind Body Syndrome Therapy for Chronic Pain","Mind Body Syndrome Therapy for the Treatment of Chronic Pain","Inclusion Criteria:\n\n* Adult patient 18 ≥ years old\n* Chronic back pain\n* Pain persistent for a minimum of 3 days a week for the past three months prior to enrollment\n* Willingness to consider mind-body intervention\n* At least score of 2 or more on Roland Disability Questionnaire\n* At least score of 3 or more back pain bothersomeness\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age\n* Patients \\> 67 years of age\n* Diagnosed organic disease as cause of pain, such as (but not limited) to malignancy, neurologic disorder (i.e., amyotrophic lateral sclerosis), cauda equina syndrome (note that pain related to disc disease is not an exclusion unless there are neurological impairments)\n* Patients with a diagnosis of significant psychiatric co-morbidities such as schizophrenia, dementia, and bipolar disorder","67 Years",{"count":215,"type":19},150,[114],"The goal of this study is to determine if a mind-body intervention can help people suffering from chronic back pain. The study is a randomized, partially blinded trial examining the effectiveness of a mind body intervention in reducing disability from back pain and alleviating back pain in participants as compared to usual care and an active control (second mind body intervention). The investigators will secondarily investigate whether the intervention alleviates anxiety related to the pain and other quality of life parameters.",[23,35],"2026-03-15",{"date":221,"type":41},"2026-03-17",{"date":223,"type":41},"2021-05-20",{"date":225,"type":19},"2027-06",{"name":227,"class":48},"Beth Israel Deaconess Medical Center",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":59,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":49},"100585561","mind-body-intervention-for-chronic-upper-extremity-pain-repetitive-stress-injury-100585561","NCT06903962","Mind Body Intervention for Chronic Upper Extremity Pain (Repetitive Stress Injury)","Inclusion Criteria:\n\n1. Adult (≥ 18 years of age)\n2. A disability score ≥ 40 as per the QuickDASH survey\n3. Presence of pain and perceived disability for a minimum of 3 months\n4. Willing to engage in a Mind-Body intervention\n5. Positive visualization test (onset of pain when patients visualize themselves performing tasks that generally bring on pain)\n\nExclusion Criteria:\n\n1. Clear organic diagnosis of pain (e.g., cancer, infection, etc…) not inclusive of non-specific findings on imaging studies (e.g., mild arthritis)\n2. Age greater than 60 years (due to an increased risk of there being an organic\u002Fphysical cause for their pain and confounding results)\n3. Diagnosis of cognitive impairment or dementia\n4. Active addiction disorder, e.g. cocaine or IV heroin use, that would interfere with study participation\n5. Major psychiatric comorbidity (e.g., schizophrenia). Anxiety and mild-moderate depression are not considered in this category","60 Years",{"count":236,"type":19},40,[114],"The goal of this nonrandomized pilot study is to test a mind-body interventional approach for the treatment of chronic upper extremity pain or repetitive stress injury of the upper extremity (wrist\u002Fshoulder\u002Felbow).\n\n1. To determine if a mind-body intervention improves upper extremity functional capacity (ie., Disability of Arm Shoulder Hand - DASH) among people with chronic wrist, elbow, and shoulder pain\n2. To determine if a mind-body intervention decreases pain intensity, pain-related anxiety, and overall somatic complaints in our trial participants.\n3. To tailor the intervention and the outcomes assessment procedures for conducting a trial in a population with upper extremity pain.",[23,35,240],"Repetitive Stress Injury","2026-02-16",{"date":243,"type":41},"2026-02-18",{"date":245,"type":41},"2025-03-28",{"date":247,"type":19},"2027-06-01",{"name":227,"class":48},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":15,"minAge":256,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":59,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":49},"100553030","scs-for-patient-with-painful-diabetic-neuropathy-and-peripheral-arterial-disease-100553030","NCT06480786","SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease","Spinal Cord Stimulation for Patients With Painful Diabetic Neuropathy and Peripheral Arterial Disease: Mechanistic Insights From a Single-center, Randomized, Blinded, Sham-controlled Cross-over Proof-of-concept Trial","Inclusion Criteria:\n\n* 19 years to 89 years old\n* Diagnosed diabetes mellitus\n* Signs or symptoms of neuropathy and maximum baseline visual-analog pain scale ≥ 5 cm and peripheral arterial disease (diagnosed by ankle-brachial index \\\u003C 0.90 or vascular imaging studies) with claudication and exertion-induced visual-analog pain scale ≥ 6 cm for a minimum of 3 months\n* Successful spinal cord stimulator (SCS) trial (\\>50% relief of chronic lower extremity pain) and will have a new permanent SCS placed prior to study intervention\n\nExclusion Criteria:\n\n* Uncontrolled psychological or psychiatric disorder\n* Inability to hold antithrombotic therapy per the American Society of Regional Anesthesia guidelines\n* Non-healing wounds\n* Gangrene\n* Critical limb ischemia\n* Prior lower extremity amputation\n* Inability to adhere to study follow-up\n* Mechanical spine instability based on flexion\u002Fextension radiographs of the lumbar spine\n* Prior or current spinal cord stimulator implant","19 Years","89 Years",{"count":259,"type":19},15,[114],"Peripheral arterial disease (PAD) affects over 230 million adults worldwide and is a highly morbid, costly, and disabling condition. Ischemic leg pain drives disability in PAD patients and results from oxygen supply-demand mismatch, autonomic dysfunction, and muscle breakdown. This leg pain, which is unresponsive to traditional pharmacotherapy, limits the patient's tolerance to exercise, which is an important disease-modifying intervention. Spinal cord stimulation is a well-established therapy for medically intractable pain, including painful diabetic neuropathy (PDN) and ischemic pain, but is not part of the standard-of-care for PAD despite limited promising clinical data. Early studies used first-generation, tonic stimulation devices, but with these it was impossible to perform sham-controlled trials to test the treatment. Since then, new types of waveform treatments, including high-frequency spinal cord stimulation (SCS), have been shown to be more effective in the treatment of intractable pain. While high-frequency SCS is approved for PDN treatment, it has never been tested in the treatment of claudication pain from PAD.\n\nThis study will enroll up to 15 participants between the ages of 19 and 89 who have PAD and PDN and are successfully implanted with a permanent SCS. Twelve weeks after SCS implantation, participants will receive two weeks of stimulation and two weeks of sham intervention, in random starting order. Blood flow, blood pressure, skin oxygen levels, and participant reported pain int the lower extremities will be assessed before SCS implantation, 12 weeks after SCS implantation and during each of the treatment periods. Participants will also complete a quality of life survey at the same time points. Comparisons of these measurements with the baseline and post-implantation measurements to determine the effects of SCS.",[263,264,265,23,266,35,267],"Peripheral Arterial Disease","Painful Diabetic Neuropathy","Diabetes Mellitus, Type 2","Spinal Cord Stimulation","Limb Pain","2025-10-21",{"date":270,"type":41},"2025-10-22",{"date":272,"type":41},"2024-12-18",{"date":274,"type":19},"2027-07",{"name":276,"class":48},"University of Nebraska",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":283,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":286,"conditions":287,"keywords":308,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":49},"100497203","assessing-symptom-and-mood-dynamics-in-pain-using-the-smartphone-application-soma-100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",true,{"count":285,"type":19},800,"This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[23,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,264,304,305,306,35,307],"Acute Pain","Post Operative Pain","Fibromyalgia, Primary","Fibromyalgia, Secondary","Fibromyalgia","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Migraine","Chronic Pelvic Pain Syndrome","Temporomandibular Joint Disorders","Endometriosis-related Pain","Arthritis","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Shoulder Pain",[309,310,311,191,312,313,314,315,316],"digital health","e-health","smartphone application","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":319,"type":41},"2025-09-19",{"date":321,"type":41},"2023-06-20",{"date":323,"type":19},"2026-05-30",{"name":325,"class":48},"Brown University",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":283,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100556598","fibromyalgia-and-small-fiber-neuropathy-100556598","NCT06527183","Fibromyalgia and Small Fiber Neuropathy","Fibromyalgia and Small Fiber Neuropathy : Which Prevalence and Which Relationship With Pain ?","FIBRO-NEP","Inclusion Criteria:\n\n* patients over 18 years of age with no age limit -\n* having given their signed consent to take part in the study\n* affiliated to the French social security system\n* able to be followed for the entire duration of the study\n* reading and understanding French\n* accepting the principle of the study and able to comply with its conditions\n* suffering from chronic pain for at least six months of at least moderate intensity (≥ 4\u002F10)\n* fibromyalgia detected by the FiRST questionnare and defined by the revised diagnostic criteria of the WHO or chronic nociceptive or nociplastic pain without associated fibromyalgia.\n* chronic pain for at least 6 months of at least moderate intensity (≥ 4\u002F10)\n* untreated or with stable analgesic treatment for at least 2 weeks prior to inclusion- normal neurological examination at inclusion\n\nExclusion Criteria:\n\n* litigation or compensation-seeking\n* cancer for less than 2 years\n* known cause of small-fiber neuropathy such as diabetes, systemic disease, hypothyroidism, alcohol, renal failure, genetic disease\n* clinical or EMG neuropathy\n* peripheral or central nervous system pathology with or without associated neuropathic pain\n* uncontrolled chronic pathology such as : morbid obesity, sleep apnea, uncontrolled hypertension, etc. - psychosis, previous suicide attempt\n* drug or psychoactive substance abuse\n* cognitive or psychological disorders incompatible with compliance with and\u002For understanding of the protocol\n* participation in another biomedical research protocol.",{"count":215,"type":19},"The primary objective of this study will be to assess the proportion of fibromyalgia patients with diffuse small-fiber neuropathy (i.e. in the upper and lower limbs) and compare this proportion to patients with other chronic pains (nociplastic, nociceptive) and with healthy controls. Our analysis will be based on the demonstration of structural abnormalities of small nerve fibers by means of skin biopsy, but also of functional abnormalities using four validated tests commonly used in this field: quantitative sensory testing (QST), laser evoked potential recordings, Sudoscan and confocal corneal microscopy. It will thus be possible to verify whether or not patients with small fiber neuropathy have a particular clinical profile in terms of pain, physical activity, comorbidities or pain impact.",[35],"2025-09-03",{"date":339,"type":41},"2025-09-10",{"date":341,"type":41},"2022-01-04",{"date":343,"type":19},"2026-05",{"name":345,"class":48},"Hospital Ambroise Paré Paris",2,{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":15,"minAge":256,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":59,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":49},"100603967","evaluation-of-a-mind-body-based-approach-for-chronic-pain-treatment-100603967","NCT07143396","Evaluation of a Mind-Body Based Approach for Chronic Pain Treatment","Evaluation of a Mind-Body Application in Combination With a Graded Movement Program for the Treatment of Chronic Pain","Inclusion Criteria:\n\n* Participants aged 19 to 75 years with chronic pain\n* Chronic pain is defined as having non-malignant chronic or persistent pain for at least 6 months.\n* Participants must experience pain at least half the days in the last 6 months.\n* Pain can include bodily pain or head (migraine) pain\n* Participants must have access to an electronic device\n* Participants must be willing to engage in weekly somatic education activities\n\nExclusion Criteria:\n\n* Individuals reporting a cognitive impairment that can interfere with completing questionnaires and using a mobile application.\n* Individuals reporting substance use disorder (within the last 6 months).\n* Individuals reporting any of the following medical conditions: metastatic cancer, rheumatoid arthritis, lupus, scleroderma, polymyositis.\n* Individuals with previous experience with the mind-body app under study (Note: use of \"Calm\" or another meditation-only app is not an exclusion).\n* Individuals with current regular (at least once a week) engagement with a somatic movement program (e.g., Feldenkrais, Hanna Somatics, Somatic Yoga, Tai Chi, Pilates)","75 Years",{"count":58,"type":19},[114],"The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic\u002Fpersistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).",[23,359,35],"Migraine",[361,362,191,363,364],"mind-body","mobile application","guided movement","Somatic Education","2025-08-29",{"date":367,"type":41},"2025-09-08",{"date":369,"type":19},"2025-10",{"date":371,"type":19},"2025-12",{"name":373,"class":48},"University of the Fraser Valley",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":15,"minAge":382,"maxAge":16,"enrollmentInfo":383,"targetDuration":4,"studyType":59,"phases":384,"briefSummary":385,"conditions":386,"keywords":392,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":346},"100587531","shiatsu-for-chronic-non-inflammatory-pain-in-children-and-adolescents-100587531","NCT06929598","Shiatsu for Chronic Non-Inflammatory Pain in Children and Adolescents","The Efficacy of Adjunctive Shiatsu Therapy for Non-Inflammatory Chronic Pain in Pediatric Patients: A Single-Arm Prospective Trial","ShiQoL","Inclusion Criteria:\n\n* Children and adolescents aged 10-18 years\n* Diagnosed with non-inflammatory chronic pain syndromes\n* Actively followed by the Pediatric Rheumatology and\u002For Pediatric Pain Clinics at Tel Aviv Sourasky Medical Center (at least twice a year)\n* Informed consent signed by at least one legal guardian (or both guardians in cases of separated parents)\n* If participant is 16 years or older, they must also sign the informed consent\n\nExclusion Criteria:\n\n* Informed consent cannot be obtained from the participant or their legal guardians\n* Legal guardians unable to provide informed consent\n* Patients with severe conditions (e.g., bone metastasis)\n* Patients unable to participate in Shiatsu therapy sessions\n* Participation in Shiatsu therapy within 6 months prior to study enrollment\n* Participant or legal guardian refuses participation","10 Years",{"count":236,"type":19},[114],"The goal of this clinical trial is to learn if adding Shiatsu therapy to standard treatment can improve quality of life in children and adolescents with chronic pain that is not caused by inflammation. The main question it aims to answer is: Does Shiatsu therapy help improve the quality of life in children with long-lasting pain?\n\nAll participants will continue their regular treatment and will also:\n\n* Receive a 30-minute Shiatsu session once a week for six weeks\n* Complete questionnaires about their quality of life and family impact before, during, and after the treatment period\n\nThe study includes about 40 participants between the ages of 10 and 18, who are already being followed at the pediatric pain and rheumatology clinics at Tel Aviv Sourasky Medical Center.",[23,35,387,388,389,292,390,391],"Chronic Pain and Comorbid Emotional Problems","Chronic Pain, Psychogenic","Chronic Pain, Widespread","Fibromyalgia Syndrome","Functional Pain",[393,394,395,396,397,398,399,400,401,402,403,391,404],"Shiatsu","Complementary and Integrative Medicine","Pediatric Chronic Pain","Non-inflammatory Pain","Quality of Life","PedsQL","Adolescent Pain","Manual Therapy","Mind-Body Therapy","Pediatric Rheumatology","Integrative Medicine","Pain Management","2025-08-27",{"date":407,"type":41},"2025-09-04",{"date":409,"type":41},"2025-05-01",{"date":411,"type":19},"2027-04-30",{"name":413,"class":48},"Tel Aviv University",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":59,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":49},"100590194","protocol-assessment-of-motor-cortex-rtms-for-treating-neuropathic-pain-100590194","NCT06964243","Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain","Classical, Spaced, or Accelerated Transcranial Magnetic Stimulation of Motor Cortex for Treating Neuropathic Pain: a 3-arm Parallel Non-inferiority Study","CSA3-RTMS","Inclusion Criteria:\n\n* (1) existence of a definite peripheral neuropathy on both clinical and neurophysiological grounds, present for at least 6 months;\n* (2) neuropathic pain clearly related to the neuropathy, as defined by a score ≥ 4\u002F10 on the questionnaire \"Douleur Neuropathique en 4 Questions\" (DN4) ;\n* (3) a score ≥ 4\u002F10 on a 0-10 numerical rating scale (NRS) concerning the average intensity of daily ongoing pain;\n* (4) age between 18 and 80 years;\n* (5) affiliation with the social security system;\n* (6) ability to provide signed informed consent.\n\nExclusion Criteria:\n\n* (1) concomitant neurological (neurodegenerative disorders, migraine, epilepsy, stroke, tumor) or psychiatric illness;\n* (2) contraindications related to TMS (intracranial ferromagnetic material);\n* (3) drug-resistant or active epilepsy.","80 Years",{"count":424,"type":19},36,[114],"Neuropathic pain is frequent and drugs relieves only 50% of the patients. Repetitive transcranial magnetic stimulation (rTMS) at high frequency (HF, usually 10Hz) applied on the primary motor cortex (M1) is an effective treatment of neuropathic pain. For the treatment of chronic pain, the 'classical' HF-rTMS protocol (CHF-rTMS) include one daily session for one or two weeks as an induction phase of treatment followed by a weekly session to produce analgesic effects. However, another type of protocol is based on a more spaced repetition of HF-rTMS sessions (SHF-rTMS), including intervals of several days or weeks between two sessions, but also resulting in a significant pain relief. However, CHF-rTMS and SHF-rTMS have never been compared regarding their analgesic efficacy.\n\nAlongside with pain, depression is the other clinical condition for which HF-rTMS is proposed as an effective therapeutic strategy. Another type of rTMS paradigm, called \"accelerated intermittent theta burst stimulation\" (ACC-iTBS) protocol has been recently proposed for the treatment of depression, combining a high number of pulses delivered per session and a high number of short-duration sessions grouped into a few days of stimulation. However, this type of protocol has never been applied for the treatment of chronic pain patients.\n\nThus, for the first time we propose to compare in a pilot study the efficacy of three different rTMS protocols for the treatment of chronic neuropathic: CHF-rTMS, SHF-rTMS, and ACC-iTBS. In this study, two protocols two rTMS protocols (CHF-rTMS and ACC-iTBS) will share the same high total number of TMS pulses (i.e. 30 000 pulses) versus an rTMS protocol (SHF-rTMS) based on a lower total number of TMS pulses (i.e. 6 400 pulses), while one protocol (CHF-rTMS) will include a higher number of days of stimulation (i.e. 10 days) compared to the two other protocols (ACC-iTBS and SHF-rTMS) (i.e. 4 days). In all cases, the motor cortical target and the intensity of stimulation will the same.\n\nThus, this study will be able to appraise the respective influence of the number of pulses delivered (the higher the number, the greater the effect) and the number of sessions (the higher the number, the more restrictive the implementation of treatment). That is to say that the new ACC-iTBS protocol could be an optimal compromise of a more efficacious and more easy-to-perform rTMS protocol for the treatment of patients with chronic pain.",[35,428],"Peripheral Neuropathic Pain",[430,431,432,433,191,434,435,436,437,438],"rTMS","TMS-EEG","EEG","neuropathic pain","peripheral neuropathy","treatment","TBS","thetaburst stimulation","transcranial magnetic stimulation","2025-04-30",{"date":441,"type":41},"2025-05-09",{"date":443,"type":41},"2025-04-01",{"date":445,"type":19},"2027-02-01",{"name":447,"class":48},"Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":283,"sex":15,"minAge":234,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":59,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":49},"100545883","the-development-of-a-gamified-web-based-pain-management-program-gap-for-community-dwelling-older-adults-with-chronic-pain-100545883","NCT06387706","The Development of a Gamified Web-based Pain Management Program (GAP) for Community-dwelling Older Adults With Chronic Pain","Inclusion Criteria:\n\n* Aged 60 or above\n* Can understand Cantonese\n* Scored \\>6 in the Abbreviated Mental Test; a cut-off point of 6 is valid for differentiating between normal and abnormal cognitive functions in geriatric clients\n* Have a history of non-cancer pain in the past 6 months\n* Have a pain score of at least 2 on the Numeric Rating Scale\n* Able to take part in light exercise and stretching\n* Owns a smartphone and can access the Internet\n\nExclusion Criteria:\n\n* Have severe visual and\u002For auditory deficits that affect that seeing and hearing\n* Have a serious organic disease or malignant tumor\n* Have a mental disorder diagnosed by neurologists or psychiatrists\n* Had a surgical treatment in the past two months\n* Experienced drug addiction",{"count":455,"type":19},4,[114],"Pain Management in Older Adults: Pain significantly impacts the well-being of older adults, often leading to diminished physical abilities and a reduced quality of life. Despite this, pain management remains suboptimal, with concerns about medication side effects and a tendency to view pain as a natural aspect of aging. Consequently, many seniors are hesitant to use painkillers. As an alternative, non-pharmacological strategies such as educational programs, physical activity, massage, relaxation techniques, and music therapy are gaining traction.\n\nInnovative Non-Drug Solutions: To improve participation in non-medication pain relief methods, we suggest incorporating gaming elements into these programs (GAP). Originating in digital media in 2008, gamification has since spread across various industries. It involves adding game-like elements to activities to boost engagement, experience, and motivation.\n\nProject Goals: The aims of this initiative include creating a web-based Gamified Pain Management Program (GAP), engaging older adults with chronic pain in the development of GAP, and gathering their feedback on the program's effectiveness.",[35],"2024-09-30",{"date":461,"type":41},"2024-10-02",{"date":463,"type":41},"2023-12-01",{"date":465,"type":19},"2025-11-30",{"name":467,"class":48},"The Hong Kong Polytechnic University",{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":283,"sex":15,"minAge":16,"maxAge":354,"enrollmentInfo":475,"targetDuration":4,"studyType":59,"phases":477,"briefSummary":478,"conditions":479,"keywords":482,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":49},"100549946","management-of-chronic-non-cancer-pain-with-non-pharmacological-therapies-100549946","NCT06440668","Management of Chronic Non-Cancer Pain With Non-Pharmacological Therapies","Management of Chronic Non-Cancer Pain With Non-Pharmacological Therapies: Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients aged 18 years or older,\n* Residing in the areas served by HSJDA,\n* With non-cancer chronic pain already diagnosed and treated for at least 6 months but not relieved by the usual treatment,\n* Who have explicitly and in writing expressed their desire to participate in the workshops and the study through the Informed Consent document,\n* And who complete the initial documentation necessary for their evaluation.\n\nExclusion Criteria:\n\n* Patients in the diagnostic phase,\n* Patients with pain exclusively associated with cancer pathology,\n* Patients with a life expectancy of less than one year,\n* Patients with severe cognitive or mental illnesses that prevent them from understanding both the content of the workshops and the measurement instruments.",{"count":476,"type":19},128,[114],"A randomized controlled clinical trial will be conducted, involving a psychoeducational activity as the intervention. There will be a control group of patients with non-cancer chronic pain who will continue their usual treatment.\n\nThe trial will end after 3 months. Pain, well-being, medication management, mood, self-esteem, and quality of life will be compared just before starting the workshop with the status at the end of the workshop (one month later) to assess the immediate effect, and three months later to evaluate the medium-term effect. These measurements will be taken in both the control and intervention groups.\n\nAdditionally, for the intervention group, a follow-up will be conducted six months after the workshop ends to assess the long-term effect duration.\n\nThis study does not allow blinding of patients or professionals conducting the intervention, but the person analyzing the data to compare the effect produced in the control and intervention groups will be blinded. Therefore, it is an observer-blind evaluation.",[35,480,397,481],"Sensitization, Central","Patient Empowerment",[35,480,397,481],"2024-06-04",{"date":485,"type":41},"2024-06-05",{"date":487,"type":19},"2024-06-10",{"date":489,"type":19},"2025-10-31",{"name":491,"class":48},"Hospital San Juan de Dios del Aljarafe de Sevilla"]